7 June 2017 - A new study published today has exposed major flaws in the fast tracking of some drugs available to the American public without any stringent clinical evidence of their benefits.
Researchers from the London School of Economics and Political Science and the United States say that many US patients with serious illnesses are being treated by drugs which have questionable data.
The findings, published in The Milbank Quarterly, relate to drugs given "accelerated approval" by the FDA without any strong clinical evaluation.